Tearsheet

Nu Skin Enterprises (NUS)


Market Price (3/20/2026): $7.15 | Market Cap: $347.3 Mil
Sector: Consumer Staples | Industry: Household Products

Nu Skin Enterprises (NUS)


Market Price (3/20/2026): $7.15
Market Cap: $347.3 Mil
Sector: Consumer Staples
Industry: Household Products

Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.

0 Attractive yield
Total YieldTotal Yield = Earnings Yield + Dividend Yield, Earnings Yield = Net Income / Market Cap Dividend Yield = Total Dividends / Market Cap is 50%, Dividend Yield is 3.4%, ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is 45%, FCF Yield is 13%
Weak multi-year price returns
2Y Excs Rtn is -70%, 3Y Excs Rtn is -149%
Weak revenue growth
Rev Chg LTMRevenue Change % Last Twelve Months (LTM) is -14%, Rev Chg 3Y AvgRevenue Change % averaged over trailing 3 years is -13%, Rev Chg QQuarterly Revenue Change % is -17%
1 Valuation becoming less expensive
P/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is -39%
  Key risks
NUS key risks include [1] persistent challenges in acquiring and retaining customers and affiliates, Show more.
2 Megatrend and thematic drivers
Megatrends include Health & Wellness Trends, Personal Care & Beauty Innovations, and E-commerce & Digital Retail. Themes include Nutritional Supplements, Show more.
  
0 Attractive yield
Total YieldTotal Yield = Earnings Yield + Dividend Yield, Earnings Yield = Net Income / Market Cap Dividend Yield = Total Dividends / Market Cap is 50%, Dividend Yield is 3.4%, ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is 45%, FCF Yield is 13%
1 Valuation becoming less expensive
P/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is -39%
2 Megatrend and thematic drivers
Megatrends include Health & Wellness Trends, Personal Care & Beauty Innovations, and E-commerce & Digital Retail. Themes include Nutritional Supplements, Show more.
3 Weak multi-year price returns
2Y Excs Rtn is -70%, 3Y Excs Rtn is -149%
4 Weak revenue growth
Rev Chg LTMRevenue Change % Last Twelve Months (LTM) is -14%, Rev Chg 3Y AvgRevenue Change % averaged over trailing 3 years is -13%, Rev Chg QQuarterly Revenue Change % is -17%
5 Key risks
NUS key risks include [1] persistent challenges in acquiring and retaining customers and affiliates, Show more.

Valuation, Metrics & Events

Price Chart

Why The Stock Moved

Qualitative Assessment

AI Analysis | Feedback

Nu Skin Enterprises (NUS) stock has lost about 25% since 11/30/2025 because of the following key factors:

1. Weak Fourth Quarter 2025 Revenue Performance and Declining Customer Base. Nu Skin Enterprises reported fourth quarter 2025 revenue of $370.3 million, a 16.9% decrease year-over-year, falling short of analyst expectations of approximately $392.1 million. This revenue decline was accompanied by significant drops in customer metrics, with total customers down 10%, paid affiliates down 11%, and sales leaders experiencing a 19% year-over-year decrease. Regional performance also showed broad-based revenue declines, particularly in South Korea (-28%) and Mainland China (-21%) in terms of customer losses.

2. Disappointing First Quarter and Full-Year 2026 Financial Guidance. The company issued Q1 2026 earnings per share (EPS) guidance of $0.10 to $0.20, substantially below the consensus estimate of $0.29. Similarly, Q1 2026 revenue guidance was projected at $320 million to $340 million, missing the consensus estimate of $382.7 million. For the full fiscal year 2026, Nu Skin provided revenue guidance of $1.35 billion to $1.50 billion and EPS guidance of $0.80 to $1.20, with the revenue midpoint ($1.425 billion) below the analyst sales consensus of $1.545 billion. This conservative outlook signaled ongoing challenges and a slower-than-anticipated return to growth.

Show more

Stock Movement Drivers

Fundamental Drivers

The -27.3% change in NUS stock from 11/30/2025 to 3/19/2026 was primarily driven by a -51.1% change in the company's P/E Multiple.
(LTM values as of)113020253192026Change
Stock Price ($)9.827.14-27.3%
Change Contribution By: 
Total Revenues ($ Mil)1,5601,485-4.8%
Net Income Margin (%)7.0%10.8%53.6%
P/E Multiple4.42.2-51.1%
Shares Outstanding (Mil)49491.7%
Cumulative Contribution-27.3%

LTM = Last Twelve Months as of date shown

Market Drivers

11/30/2025 to 3/19/2026
ReturnCorrelation
NUS-27.3% 
Market (SPY)-3.5%14.4%
Sector (XLP)3.3%18.8%

Fundamental Drivers

The -40.6% change in NUS stock from 8/31/2025 to 3/19/2026 was primarily driven by a -63.3% change in the company's P/E Multiple.
(LTM values as of)83120253192026Change
Stock Price ($)12.027.14-40.6%
Change Contribution By: 
Total Revenues ($ Mil)1,6261,485-8.7%
Net Income Margin (%)6.2%10.8%74.0%
P/E Multiple5.92.2-63.3%
Shares Outstanding (Mil)49491.8%
Cumulative Contribution-40.6%

LTM = Last Twelve Months as of date shown

Market Drivers

8/31/2025 to 3/19/2026
ReturnCorrelation
NUS-40.6% 
Market (SPY)2.6%25.4%
Sector (XLP)2.2%2.0%

Fundamental Drivers

The -7.6% change in NUS stock from 2/28/2025 to 3/19/2026 was primarily driven by a -14.3% change in the company's Total Revenues ($ Mil).
(LTM values as of)22820253192026Change
Stock Price ($)7.727.14-7.6%
Change Contribution By: 
Total Revenues ($ Mil)1,7321,485-14.3%
P/S Multiple0.20.25.3%
Shares Outstanding (Mil)50492.3%
Cumulative Contribution-7.6%

LTM = Last Twelve Months as of date shown

Market Drivers

2/28/2025 to 3/19/2026
ReturnCorrelation
NUS-7.6% 
Market (SPY)12.0%31.4%
Sector (XLP)0.6%18.3%

Fundamental Drivers

The -80.0% change in NUS stock from 2/28/2023 to 3/19/2026 was primarily driven by a -87.2% change in the company's P/E Multiple.
(LTM values as of)22820233192026Change
Stock Price ($)35.787.14-80.0%
Change Contribution By: 
Total Revenues ($ Mil)2,2261,485-33.3%
Net Income Margin (%)4.7%10.8%129.1%
P/E Multiple16.92.2-87.2%
Shares Outstanding (Mil)49491.8%
Cumulative Contribution-80.0%

LTM = Last Twelve Months as of date shown

Market Drivers

2/28/2023 to 3/19/2026
ReturnCorrelation
NUS-80.0% 
Market (SPY)72.7%25.6%
Sector (XLP)22.4%21.5%

Return vs. Risk

Price Returns Compared

 202120222023202420252026Total [1]
Returns
NUS Return-4%-14%-51%-64%43%-25%-84%
Peers Return19%-48%7%-45%19%-2%-58%
S&P 500 Return27%-19%24%23%16%-3%76%

Monthly Win Rates [3]
NUS Win Rate42%50%25%33%42%33% 
Peers Win Rate67%27%53%38%42%47% 
S&P 500 Win Rate75%42%67%75%67%33% 

Max Drawdowns [4]
NUS Max Drawdown-26%-36%-60%-68%-20%-26% 
Peers Max Drawdown-8%-55%-28%-52%-34%-9% 
S&P 500 Max Drawdown-1%-25%-1%-2%-15%-3% 


[1] Cumulative total returns since the beginning of 2021
[2] Peers: HLF, USNA, NATR, MED, EL. See NUS Returns vs. Peers.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 3/19/2026 (YTD)

How Low Can It Go

Unique KeyEventNUSS&P 500
2022 Inflation Shock2022 Inflation Shock  
2022 Inflation Shock% Loss% Loss-73.8%-25.4%
2022 Inflation Shock% Gain to Breakeven% Gain to Breakeven282.4%34.1%
2022 Inflation ShockTime to BreakevenTime to BreakevenNot Fully Recovered days464 days
2020 Covid Pandemic2020 Covid Pandemic  
2020 Covid Pandemic% Loss% Loss-70.5%-33.9%
2020 Covid Pandemic% Gain to Breakeven% Gain to Breakeven239.5%51.3%
2020 Covid PandemicTime to BreakevenTime to Breakeven106 days148 days
2018 Correction2018 Correction  
2018 Correction% Loss% Loss-55.9%-19.8%
2018 Correction% Gain to Breakeven% Gain to Breakeven126.6%24.7%
2018 CorrectionTime to BreakevenTime to BreakevenNot Fully Recovered days120 days
2008 Global Financial Crisis2008 Global Financial Crisis  
2008 Global Financial Crisis% Loss% Loss-59.1%-56.8%
2008 Global Financial Crisis% Gain to Breakeven% Gain to Breakeven144.7%131.3%
2008 Global Financial CrisisTime to BreakevenTime to Breakeven210 days1,480 days

Compare to HLF, USNA, NATR, MED, EL

In The Past

Nu Skin Enterprises's stock fell -73.8% during the 2022 Inflation Shock from a high on 6/9/2021. A -73.8% loss requires a 282.4% gain to breakeven.

Preserve Wealth

Limiting losses and compounding gains is essential to preserving wealth.

Asset Allocation

Actively managed asset allocation strategies protect wealth. Learn more.

About Nu Skin Enterprises (NUS)

Nu Skin Enterprises, Inc. develops and distributes beauty and wellness products worldwide. It provides skin care systems, including ageLOC Spa systems, ageLOC Transformation anti-aging skin care systems, and ageLOC LumiSpa skin treatment and cleansing devices; and ageLOC Boost, as well as a range of other cosmetic and personal care products. The company also offers ageLOC Youth nutritional supplements, ageLOC TR90 weight management and body shaping systems, LifePak nutritional supplements, ageLOC Meta nutritional supplements, and Beauty Focus Collagen+ skin care supplements, as well as other weight management products. In addition, it is involved in the research and product development of skin care products and nutritional supplements. Further, the company operates retail stores and service centers in Mainland China. It sells its products under the Nu Skin, Pharmanex, and ageLOC brands. The company promotes and sells its products directly, as well as through distributors and Website. Nu Skin Enterprises, Inc. was founded in 1984 and is headquartered in Provo, Utah.

AI Analysis | Feedback

Here are 1-3 brief analogies for Nu Skin Enterprises:

  • The Mary Kay or Avon for anti-aging beauty and wellness.
  • The Herbalife for premium anti-aging skincare and nutritional supplements.
  • Imagine Mary Kay meets Herbalife, selling beauty and wellness products through direct sales.

AI Analysis | Feedback

  • ageLOC Spa Systems: Anti-aging skin care systems designed to rejuvenate the skin.
  • ageLOC Transformation Systems: Comprehensive anti-aging skin care systems targeting the sources of aging.
  • ageLOC LumiSpa Devices: Handheld devices used for deep skin treatment and cleansing.
  • ageLOC Boost: A cosmetic product that enhances skin appearance and luminosity.
  • ageLOC Youth Nutritional Supplements: Supplements formulated to promote overall wellness and anti-aging benefits.
  • ageLOC TR90: A weight management and body shaping system.
  • LifePak Nutritional Supplements: General nutritional supplements providing essential vitamins and minerals.
  • ageLOC Meta Nutritional Supplements: Specialized nutritional supplements focused on metabolic health.
  • Beauty Focus Collagen+ Supplements: Supplements specifically designed to support skin health and appearance through collagen.

AI Analysis | Feedback

Nu Skin Enterprises (NUS) sells primarily to individuals. The company operates a direct sales model, promoting and selling its beauty and wellness products directly, through distributors, and via its website. Here are the major categories of customers that Nu Skin Enterprises serves:
  1. Consumers Focused on Beauty and Anti-Aging: This category includes individuals interested in skincare, anti-aging solutions, and cosmetic products. They seek to improve their appearance, reduce signs of aging, and maintain youthful skin using products such as ageLOC Spa systems, ageLOC LumiSpa, ageLOC Transformation, ageLOC Boost, and Beauty Focus Collagen+.
  2. Consumers Focused on Health, Wellness, and Weight Management: This group comprises individuals who prioritize their internal health, seeking nutritional supplements, general wellness products, and weight management solutions. Products like ageLOC Youth, ageLOC TR90, LifePak, and ageLOC Meta cater to their needs for better health and physical well-being.
  3. Entrepreneurs and Direct Sellers (Distributors): While also a sales channel, individuals who join Nu Skin's network as distributors are a significant customer segment. They purchase products directly from Nu Skin with the intention of reselling them to other individual consumers, often building their own sales teams. Their motivation includes both personal consumption and pursuing a business opportunity.

AI Analysis | Feedback

null

AI Analysis | Feedback

Ryan Napierski, Chief Executive Officer & President

Ryan Napierski has served as Nu Skin's chief executive officer and president since his appointment in March 2017. He joined Nu Skin Enterprises in 1995 and has held numerous leadership positions within the company, including president of global sales and operations, president of Nu Skin's North Asia region, and president of Nu Skin Japan. His other roles included vice president of global business development, general manager for the United Kingdom, vice president of European business development, key account manager for U.S. executives, and chief operating officer for the North Asia region. Napierski holds a bachelor's degree in business, a Master of Business Administration from Duke University, and a master's degree in international business from Goethe Universität in Germany. He also serves as the Chairman of the U.S. Direct Selling Association and holds positions on the Direct Selling Board of Directors, Direct Selling Education Foundation, and The World Federation of Direct Selling Association.

James D. Thomas, Executive Vice President, Chief Financial Officer

James D. Thomas was appointed Chief Financial Officer of Nu Skin Enterprises in 2023. Prior to this role, he served as senior vice president and chief accounting officer for the company starting in 2019. His previous experience at Nu Skin includes serving as vice president of global accounting and reporting, and vice president of finance and accountability. Thomas has been instrumental in the company's mergers and acquisitions strategy and has led various projects focused on globally aligning financial operations and identifying efficiencies to improve margins.

Joseph Y. Chang, Ph.D., Chief Scientific Officer & Executive Vice President, Product Development

Joseph Y. Chang, Ph.D., has served as Nu Skin's chief scientific officer and executive vice president of Product Development since February 2006. He possesses extensive knowledge of both the pharmaceutical and dietary supplement industries. Before joining Nu Skin, Dr. Chang was president and chief scientific officer of Pharmanex, and prior to that, he held the same positions at Binary Therapeutics, Inc. (1994-1997) and OsteoArthritis Sciences, Inc. (1991-1994). He also held executive research management roles at Wyeth-Ayerst, Rhone Poulenc Rorer, and other biotechnology companies, focusing on research for natural products related to arthritis and cancer treatment. Dr. Chang earned a B.S. degree from Portsmouth University and a Ph.D. from the University of London. He is a prolific author, having published numerous articles, reviews, and books on pharmacological research, including "The Aging Myth."

Chayce Clark, Executive Vice President and General Counsel

Chayce Clark is the executive vice president and general counsel of Nu Skin Enterprises, a role he assumed in August 2021, overseeing global legal affairs. He joined Nu Skin in 2015 as assistant general counsel and later became vice president and deputy general counsel. Prior to his tenure at Nu Skin, Clark worked as a litigation attorney at the law firm of Jones, Waldo, Holbrook & McDonough. He holds a bachelor's degree in accounting from Southern Utah University and a J.D. from the University of Utah.

Steve Hatchett, Executive Vice President, Chief Product Officer

Steve Hatchett was appointed executive vice president and chief product officer in 2021. Before this, he served as the senior vice president of global products and has been a member of Nu Skin's global management committee since 2018.

AI Analysis | Feedback

The key risks to Nu Skin Enterprises (NUS) are primarily associated with its direct selling business model, its significant reliance on the Chinese market, and broader economic factors impacting consumer spending and its salesforce.

  1. Regulatory Scrutiny of Direct Selling and Challenges in the China Market: Nu Skin's direct selling model is subject to extensive global regulatory oversight, particularly in markets like China, which is crucial for the company's revenue. The company has faced past investigations and fines in China for violating direct selling laws and for misleading claims by distributors, as well as allegations of operating an illegal pyramid scheme. Any future modifications to direct selling regulations, stricter enforcement, or negative media attention in China could significantly impact Nu Skin's revenue, sales force, and business operations in this vital market.

  2. Declining Sales, Shrinking Affiliate Base, and Intense Competition: Nu Skin has experienced consistent revenue declines over recent years, coupled with a significant reduction in its paid affiliates and sales leaders. The beauty, wellness, and direct selling industries are highly competitive, with evolving consumer preferences increasingly favoring social media-driven product discovery and influencer marketing over traditional direct selling methods. This competitive landscape and changing consumer habits make it challenging for Nu Skin to attract and retain distributors and maintain sales growth.

  3. Macroeconomic Pressures and Impact on Consumer Spending: Economic slowdowns, inflation, tariffs, and geopolitical uncertainties negatively affect consumer spending, especially on premium beauty and wellness products, which constitute a significant portion of Nu Skin's offerings. Consumers in key markets such as Greater China, South Korea, and North America have shown caution in purchasing premium products due to these macroeconomic headwinds, impacting Nu Skin's financial performance.

AI Analysis | Feedback

1. Increasing competition from direct-to-consumer (DTC) beauty and wellness brands and broader e-commerce platforms: The market is seeing a proliferation of online-first brands in skincare, supplements, and weight management that leverage digital marketing, transparent ingredient sourcing, and competitive pricing to reach consumers directly. These brands bypass traditional multi-level marketing (MLM) structures, offering convenience and often appealing more to younger demographics who prefer online purchasing and independent product reviews over distributor relationships. This trend directly challenges Nu Skin's established distribution model and market share in its core product categories.

2. Heightened regulatory scrutiny and potential for tightened restrictions on multi-level marketing (MLM) business practices: Nu Skin operates using a direct selling model which is often subject to intense regulatory oversight concerning distributor compensation plans, earnings claims, and product efficacy substantiation. Key markets, particularly Mainland China, have historically implemented strict regulations on direct selling and anti-pyramid scheme laws. Any future tightening of these regulations, increased enforcement actions, or shifts in legal interpretations could severely impact Nu Skin's ability to operate its distributor network and recruit new participants, fundamentally challenging its core business model.

AI Analysis | Feedback

Nu Skin Enterprises (symbol: NUS) operates within several substantial addressable markets globally and in key regions like China, encompassing beauty and wellness products, nutritional supplements, and weight management solutions.

Beauty and Personal Care Products

  • The global anti-aging products market was valued at $55.8 billion in 2023 and is projected to reach $108.5 billion by 2033.
  • For anti-aging cosmetics, the global market size was estimated at $60.11 billion in 2025 and is predicted to increase to approximately $106.98 billion by 2035.
  • The global beauty devices market is projected to rise from US$52.3 billion in 2025 to US$132.5 billion by 2032. Another estimate places the global beauty devices market size at USD 77.81 billion in 2025, expected to reach around USD 381.52 billion by 2035.
  • In China, a significant market for Nu Skin, the beauty and personal care market is forecast to reach a substantial revenue of US$73.66 billion in 2025. The skincare market in China, a major segment, increased from RMB332.9 billion in 2019 to RMB461.9 billion in 2024, representing a CAGR of 6.8%.

Nutritional Supplements

  • The global nutritional supplements market size was estimated at USD 517.09 billion in 2025 and is projected to reach USD 862.51 billion by 2033. Another report estimates the market at USD 412.84 billion in 2025, expected to reach around USD 808.64 billion by 2035.
  • The Asia Pacific region held the largest share of the nutritional supplements market, accounting for 42.46% in 2025.

Weight Management

  • The global weight management market generated a revenue of USD 142.58 billion in 2022 and is expected to reach USD 298.66 billion by 2030. Another source projects the market size to reach USD 591.7 billion in 2025 and USD 906.0 billion by 2034.
  • Asia Pacific was the dominant regional market for weight management, accounting for more than 37.68% of the revenue share in 2022.

Direct Selling Channel

  • The global direct selling market size was estimated at USD 237.36 billion in 2025 and is projected to reach USD 407.80 billion by 2033.
  • The health & wellness segment within direct selling dominated the global market with the largest market share of 35.3% in 2025.
  • Asia Pacific led the direct selling market with a share of 45.9% in 2025.

AI Analysis | Feedback

Nu Skin Enterprises (NYSE: NUS) is expected to drive future revenue growth over the next 2-3 years through several key initiatives:

  1. Global Launch and Adoption of Prysm iO: Nu Skin is strategically focusing on the global launch of Prysm iO, an intelligent wellness device, with a consumer launch anticipated in the second half of 2026. This initiative is expected to stimulate growth in product subscriptions and enhance customer lifetime value.
  2. Expansion into the Indian Market: The company is conducting pre-market activities and plans a full market opening in India during the latter half of 2026. This expansion is aimed at fostering sustainable, long-term growth for Nu Skin.
  3. Continued Introduction and Growth of Innovative Products: Nu Skin anticipates revenue contributions from the ongoing performance of recently launched products such as ageLOC WellSpa iO, RenuSpa iO, and TRMe. Additionally, the upcoming launch of new product lines, including the MYND360 cognitive health line, is expected to further support growth.
  4. Accelerated Growth of the Rhyz Ecosystem: Nu Skin is increasing investment in its Rhyz businesses, which have demonstrated significant growth, including a nearly 60% year-over-year increase in revenue in the first quarter of 2024. This focus on the Rhyz ecosystem aligns with the company's long-term vision of becoming an integrated beauty, wellness, and lifestyle platform.

AI Analysis | Feedback

Share Repurchases

  • Nu Skin Enterprises repurchased approximately $20 million in shares during 2025.
  • As of February 12, 2026, the company had $142.3 million remaining under its current share repurchase authorization.
  • The company's 5-Year Share Buyback Ratio was 1.80% as of September 2025, indicating share buybacks over the past five years.

Outbound Investments

  • In January 2025, Nu Skin Enterprises sold its Mavely affiliate marketing platform to Later for $250 million in cash and equity, which generated a five-times return on investment.

Capital Expenditures

  • Capital allocation priorities include investing in innovation and growth, specifically in the build-out of its intelligent wellness platform.
  • The company is focused on the global launch of its Prysm iO Intelligent Wellness device, targeting 100,000 placements by year-end 2026.
  • Nu Skin is expanding its global footprint with premarket operations in India, anticipating a formal market opening in late 2026, with a focus on local infrastructure.

Better Bets vs. Nu Skin Enterprises (NUS)

Latest Trefis Analyses

Trade Ideas

Select ideas related to NUS.

Unique KeyDateTickerCompanyCategoryTrade Strategy6M Fwd Rtn12M Fwd Rtn12M Max DD
BRBR_2272026_Dip_Buyer_High_FCF_Yield_ExInd_DE_RevG02272026BRBRBellRing BrandsDip BuyDB | FCF Yield | Low D/EDip Buy with High Free Cash Flow Yield
Buying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap
0.0%0.0%0.0%
STZ_2132026_Dip_Buyer_FCFYield02132026STZConstellation BrandsDip BuyDB | FCFY OPMDip Buy with High FCF Yield and High Margin
Buying dips for companies with high FCF yield and meaningfully high operating margin
5.7%5.7%0.0%
KMB_2132026_Insider_Buying_GTE_1Mil_EBITp+DE_V202132026KMBKimberly-ClarkInsiderInsider Buys | Low D/EStrong Insider Buying
Companies with strong insider buying in the last 1 month, positive operating income and reasonable debt / market cap
1.9%1.9%-1.7%
AVO_2062026_Insider_Buying_GTE_1Mil_EBITp+DE_V202062026AVOMission ProduceInsiderInsider Buys | Low D/EStrong Insider Buying
Companies with strong insider buying in the last 1 month, positive operating income and reasonable debt / market cap
1.1%1.1%-2.7%
CALM_1022026_Dip_Buyer_FCFYield01022026CALMCal-Maine FoodsDip BuyDB | FCFY OPMDip Buy with High FCF Yield and High Margin
Buying dips for companies with high FCF yield and meaningfully high operating margin
12.0%12.0%-7.7%
NUS_2282021_Insider_Buying_GTE_1Mil_EBITp+DE_V202282021NUSNu Skin EnterprisesInsiderInsider Buys | Low D/EStrong Insider Buying
Companies with strong insider buying in the last 1 month, positive operating income and reasonable debt / market cap
2.7%-6.6%-21.2%

Recent Active Movers

Peer Comparisons

Peers to compare with:

Financials

NUSHLFUSNANATRMEDELMedian
NameNu Skin .HerbalifeUsana He.Natures .Medifast Estee La. 
Mkt Price7.1414.8917.1424.0210.0785.6016.02
Mkt Cap0.31.50.30.40.131.00.4
Rev LTM1,4855,03891348038614,6711,199
Op Inc LTM914814225-141,41066
FCF LTM46253192911,13737
FCF 3Y Avg5921353255326756
CFO LTM80333323571,67058
CFO 3Y Avg1043256634601,79985

Growth & Margins

NUSHLFUSNANATRMEDELMedian
NameNu Skin .HerbalifeUsana He.Natures .Medifast Estee La. 
Rev Chg LTM-14.3%0.9%5.9%5.7%-36.0%-3.3%-1.2%
Rev Chg 3Y Avg-12.6%-1.1%-3.9%4.4%-37.6%-3.5%-3.7%
Rev Chg Q-16.9%6.3%6.7%4.7%-36.9%5.6%5.2%
QoQ Delta Rev Chg LTM-4.8%1.5%1.5%1.2%-10.2%1.6%1.3%
Op Mgn LTM6.1%9.5%4.6%5.2%-3.7%9.6%5.6%
Op Mgn 3Y Avg4.2%8.1%8.0%4.6%2.9%8.7%6.3%
QoQ Delta Op Mgn LTM2.2%-0.3%-1.7%0.1%-2.4%0.9%-0.1%
CFO/Rev LTM5.4%6.6%3.5%7.4%1.8%11.4%6.0%
CFO/Rev 3Y Avg6.0%6.5%7.3%7.4%6.5%12.0%6.9%
FCF/Rev LTM3.1%5.0%2.0%6.0%0.3%7.7%4.1%
FCF/Rev 3Y Avg3.4%4.2%5.9%5.4%5.4%1.8%4.8%

Valuation

NUSHLFUSNANATRMEDELMedian
NameNu Skin .HerbalifeUsana He.Natures .Medifast Estee La. 
Mkt Cap0.31.50.30.40.131.00.4
P/S0.20.30.30.90.32.10.3
P/EBIT1.73.16.414.1-7.853.64.8
P/E2.26.718.521.5-5.9-174.14.5
P/CFO4.34.69.911.916.118.610.9
Total Yield49.6%14.8%5.4%4.6%-16.7%-0.2%5.0%
Dividend Yield3.4%0.0%0.0%0.0%0.2%0.4%0.1%
FCF Yield 3Y Avg12.2%19.3%7.3%7.4%9.7%1.5%8.6%
D/E0.91.40.00.00.10.30.2
Net D/E0.21.2-0.5-0.2-1.40.20.0

Returns

NUSHLFUSNANATRMEDELMedian
NameNu Skin .HerbalifeUsana He.Natures .Medifast Estee La. 
1M Rtn-16.5%-6.6%-17.0%-9.9%-6.8%-23.4%-13.2%
3M Rtn-29.9%4.8%-15.8%6.6%-16.3%-20.4%-16.0%
6M Rtn-41.3%60.5%-44.4%43.4%-30.9%-2.1%-16.5%
12M Rtn-10.3%89.9%-37.8%84.3%-28.8%28.6%9.2%
3Y Rtn-79.8%-11.7%-72.2%123.9%-89.5%-61.8%-67.0%
1M Excs Rtn-11.4%-6.0%-5.8%-5.1%-2.0%-19.1%-5.9%
3M Excs Rtn-28.7%5.9%-12.8%10.2%-13.4%-14.9%-13.1%
6M Excs Rtn-39.1%59.8%-43.3%45.6%-28.8%-2.3%-15.6%
12M Excs Rtn-26.4%64.1%-55.7%62.5%-48.5%10.1%-8.1%
3Y Excs Rtn-148.9%-89.9%-140.5%74.1%-158.6%-130.9%-135.7%

Comparison Analyses

Financials

Segment Financials

Revenue by Segment
$ Mil20252024202320222021
Nu Skin1,7532,072   
Manufacturing181149   
Rhyz Other354   
Core Nu Skin adjustment-1    
Beauty  1,4431,4921,423
Other  190168134
Wellness  1,063923863
Total1,9692,2262,6962,5822,420


Operating Income by Segment
$ Mil20252024202320222021
Nu Skin376425   
Manufacturing124   
Rhyz Other-21-6   
Corporate and other-320-311   
Total48111   


Price Behavior

Price Behavior
Market Price$7.14 
Market Cap ($ Bil)0.3 
First Trading Date11/22/1996 
Distance from 52W High-43.7% 
   50 Days200 Days
DMA Price$9.26$9.78
DMA Trendupdown
Distance from DMA-22.9%-27.0%
 3M1YR
Volatility53.4%59.2%
Downside Capture66.6476.54
Upside Capture-144.0052.12
Correlation (SPY)13.4%31.4%
NUS Betas & Captures as of 2/28/2026

 1M2M3M6M1Y3Y
Beta0.030.570.541.120.950.87
Up Beta6.603.552.603.411.060.92
Down Beta1.771.651.111.121.231.11
Up Capture-345%-129%-71%-10%49%10%
Bmk +ve Days9203170142431
Stock +ve Days12233364123352
Down Capture-100%-31%14%98%72%102%
Bmk -ve Days12213054109320
Stock -ve Days9172759125389

[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
Annualized
Return
Annualized
Volatility
Sharpe
Ratio
Correlation
with NUS
NUS-8.8%59.1%0.07-
Sector ETF (XLP)4.8%14.1%0.1017.6%
Equity (SPY)18.7%18.8%0.7831.4%
Gold (GLD)53.5%26.8%1.59-7.2%
Commodities (DBC)18.5%17.4%0.862.1%
Real Estate (VNQ)4.4%16.1%0.0823.0%
Bitcoin (BTCUSD)-14.3%44.4%-0.229.8%

Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
Annualized
Return
Annualized
Volatility
Sharpe
Ratio
Correlation
with NUS
NUS-30.5%46.7%-0.62-
Sector ETF (XLP)7.0%13.2%0.3227.3%
Equity (SPY)12.3%17.0%0.5732.9%
Gold (GLD)21.6%17.4%1.01-0.2%
Commodities (DBC)10.8%19.0%0.463.5%
Real Estate (VNQ)3.8%18.8%0.1131.4%
Bitcoin (BTCUSD)4.4%56.7%0.3013.4%

Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
Annualized
Return
Annualized
Volatility
Sharpe
Ratio
Correlation
with NUS
NUS-11.7%49.0%-0.07-
Sector ETF (XLP)7.3%14.7%0.3720.1%
Equity (SPY)14.6%17.9%0.7031.3%
Gold (GLD)13.5%15.7%0.71-1.8%
Commodities (DBC)8.4%17.6%0.3913.1%
Real Estate (VNQ)5.5%20.7%0.2326.5%
Bitcoin (BTCUSD)67.2%66.8%1.0611.5%

Smart multi-asset allocation framework can stack odds in your favor. Learn How

Short Interest

Short Interest: As Of Date2272026
Short Interest: Shares Quantity2.1 Mil
Short Interest: % Change Since 21520262.8%
Average Daily Volume0.6 Mil
Days-to-Cover Short Interest3.6 days
Basic Shares Quantity48.6 Mil
Short % of Basic Shares4.3%

Earnings Returns History

Expand for More
 Forward Returns
Earnings Date1D Returns5D Returns21D Returns
2/12/2026-18.1%-14.1%-28.9%
11/6/2025-15.8%-9.7%-7.4%
8/7/20258.9%39.5%41.1%
5/8/202511.0%21.3%31.5%
2/13/202517.8%18.4%29.5%
11/7/20241.6%11.5%21.7%
8/8/2024-3.2%-5.1%-29.4%
5/8/20242.9%9.4%7.1%
...
SUMMARY STATS   
# Positive111112
# Negative131312
Median Positive8.9%9.8%15.5%
Median Negative-7.6%-8.9%-13.4%
Max Positive27.9%39.5%45.5%
Max Negative-20.7%-29.5%-29.4%

SEC Filings

Expand for More
Report DateFiling DateFiling
12/31/202502/13/202610-K
09/30/202511/07/202510-Q
06/30/202508/08/202510-Q
03/31/202505/09/202510-Q
12/31/202402/14/202510-K
09/30/202411/08/202410-Q
06/30/202408/09/202410-Q
03/31/202405/09/202410-Q
12/31/202302/15/202410-K
09/30/202311/02/202310-Q
06/30/202308/02/202310-Q
03/31/202305/04/202310-Q
12/31/202202/16/202310-K
09/30/202211/03/202210-Q
06/30/202208/05/202210-Q
03/31/202205/05/202210-Q

Insider Activity

Expand for More
#OwnerTitleHoldingActionFiling DatePriceSharesTransacted
Value
Value of
Held Shares
Form
1Hatchett, Steven KeithChief Product OfficerDirectBuy111220259.615,50052,8551,610,300Form
2Nathanson, Laura DirectSell904202512.226,48979,296405,081Form
3Clark, Chayce DavidEVP and General CounselDirectSell904202511.9720,000239,4002,790,686Form
4Campbell, Daniel W DirectSell829202512.129,046109,638475,298Form
5Campbell, Daniel W an irrevocable family trustSell829202512.1023,391283,031645,838Form